Inactive Instrument

Hamlet Pharma AB (publ)

Equities

HAMLET B

SE0015661152

Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).

March 30, 2023

Hamlet Pharma AB (publ) (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (publ) (NGM:SELECT B) on March 31, 2023. The transaction is subject to Hamlet Pharma AB (publ) (NGM:HAMLET B) and Selectimmune Pharma AB (publ) (NGM:SELECT B) board approval. The transaction is expected to close on May 23, 2023.

. Hamlet Pharma has engaged Advokatfirman Delphi as legal advisor. SelectImmune has engaged Falkenborn AdvokatbyrÃ¥ as legal advisor.

Latest news about Hamlet Pharma AB (publ)

Hamlet BioPharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-24	CI
Hamlet BioPharma AB Completes the First Part of A Controlled Clinical Trial in Patients with Bladder Pain Syndrome (Severe Pain in the Urinary Bladder)	05-06	CI
Hamlet BioPharma Secures Large Scale Alpha1 Peptide Production in an Agreement with Polypeptide Group	04-18	CI
Hamlet BioPharma Announces Commercial Collaborations with Top International Advisory Firms	04-11	CI
Hamlet BioPharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-22	CI
Hamlet Biopharma Announces New Analyses of Clinical Data from Alpha1h Treated Patients with Bladder Cancer Detect A Strong Immune Response with Known Anti-Tumor Effects	01-25	CI
Hamlet Biopharma AB Announces Antimicrobial Peptide Therapy for Tuberculosis Infections	12-20	CI
Hamlet Biopharma's Continued Development of Brain Tumor Therapy	12-06	CI
Hamlet BioPharma Receives U.S. FDA Fast Track Designation for Alpha 1H for the Treatment of Non-Muscle Invasive Bladder Cancer	11-29	CI
Hamlet BioPharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023	11-17	CI
Hamlet BioPharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	28/08/23	CI
Hamlet BioPharma AB Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Hamlet Pharma Announces FDA Clearance of IND Application for Alpha1H for the Treatment of Non-Muscle Invasive Bladder Cancer	01/07/23	CI
Hamlet Pharma Announces CEO Changes	30/06/23	CI
Hamlet Pharma Secures Long-Term Alpha1 Peptide Production in an Agreement with Polypeptide Group	12/06/23	CI
Hamlet Pharma Secures New Alpha1H Production Batch for Continued Clinical Trials	31/05/23	CI
Hamlet Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	26/05/23	CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	16/05/23	CI
Hamlet Pharma's Bladder Cancer Project Set for EU Commission's Full Funding	14/04/23	MT
Hamlet Pharma to Merge with SelectImmune; Shares Down 10%	31/03/23	MT
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	30/03/23	CI
Hamlet Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23/02/23	CI
Hamlet Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	11/11/22	CI
Hamlet Pharma AB Reports Earnings Results for the Full Year Ended June 30, 2022	26/08/22	CI
Hamlet Pharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	26/08/22	CI

Chart Hamlet Pharma AB (publ)

Duration

Period

More charts

Company Profile

Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company's drug candidate for bladder cancer in ongoing phase I/II clinical trials.

Sector

More about the company